Compound Summary
Compound Information
药名: | yohimbine |
别名: | Prestwick2_000584; 146-48-5; InChI=1/C21H26N2O3/c1-26-21(25)19-15-10-17-20-14(13-4-2-3-5-16(13)22-20)8-9-23(17)11-12(15)6-7-18(19)24/h2-5,12,15,17-19,22,24H,6-11H2,1H3/t12?,15?,17?,18-,19+/m0/s; (16alpha,17alpha)-17-Hydroxy-yohimban-16-carboxylic acid methyl ester; KBio3_001032; Prestwick1_000584; Yohimbic acid methyl ester; 4-25-00-01237 (Beilstein Handbook Reference); IDI1_002213; Lopac0_001210; (+)-Yohimbine; Yohimban-16alpha-carboxylic acid, 17alpha-hydroxy-, methyl ester (8CI); BRN 0097276; Johimbin; 146-48-5 (FREE BASE); Yohimbine; Bio1_001433; Yohimban-16-alpha-carboxylic acid, 17-alpha-hydroxy-, methyl ester; Corynine; 17-Hydroxy-yohimbane-16-carboxylic acid methyl ester; Bio1_000455; KBio3_001031; C09256; BSPBio_000428; 17alpha-hydroxyyohimban-16alpha-carboxylic acid methyl ester; KBio2_005712; Aphrosol; Bio2_000938; 2-Hydroxy-1,2,3,4,4a,5,7,8,13,13b,14,14a-dodecahydro-indolo[2',3':3,4]pyrido[1,2-b]isoquinoline-1-carboxylic acid methyl ester; KBioSS_000576; KBio2_000576; (+)-Yohimbin; Benz[g]indolo[2,3-a]quinolizine, yohimban-16-carboxylic acid deriv.; Yohimban-16-.alpha.-carboxylic acid, 17-.alpha.-hydroxy-, methyl ester; SMP1_000320; Yohimbol-16alpha-carboxylic acid, methyl ester (6CI); BCBcMAP01_000032; Quebrachine; KBio2_003144; BB_NC-1430; CHEBI:10093; Prestwick0_000584; EINECS 205-672-0; AIDS011945; Prestwick3_000584; 17-Hydroxyyohimban-16-carboxylic acid methyl ester; methyl (16alpha,17alpha)-17-hydroxyyohimban-16-carboxylate; Yohimbin; Bio2_000458; KBioGR_000576; NSC19509 (HCL); BSPBio_001236; AIDS-011945; 65-19-0 (HCL); Yohimban-16-carboxylic acid, 17-hydroxy-, methyl ester, (16alpha,17alpha)- (9CI); trans-Quinolizidine yohimbine; Quebrachin; (16alpha,17alpha)-17-hydroxyyohimban-16-carboxylic acid methyl ester; Yohimban-16-carboxylic acid, 17-hydroxy-, methyl ester, (16alpha,17alpha)-; nchembio705-2; Bio1_000944; methyl 17alpha-hydroxyyohimban-16alpha-carboxylate; BPBio1_000472; APHRODINE; SPBio_002647 |
分子式: | C21H26N2O3 |
Smiles: | COC(=O)C1C(CCC2C1CC3C4=C(CCN3C2)C5=CC=CC=C5N4)O |
成分: | HBIN048645 |
OB_score: | 46.417313 |
CAS_id: | 146-48-5 |
SymMap_id: | SMIT09771 |
TCMID_id: | 22905 |
TCMSP_id: | MOL008488 |
PubChem_id: | 8969 |
DrugBank_id: | DB01392 |
化合物对应的植物
| 植物ID | 拉丁名 | 药用植物名 | 药名 | 来源 | 功能与主治 | 使用民族 |
|---|
| TCMBANKHE001935 | Corynanthe johimbe | |||||
| TCMBANKHE004003 | Rauwolfia serpentina | 印度萝芙木 | To lower blood pressure./Hypertension. | |||
| TCMBANKHE004610 | Ramulus Uncariae cum Uncis | 钩藤 | To remove heat, subdue hyperactivity of the liver, and arrest convulsions./Infant fright wind and night crying, exuberant heat stirring wind, epilepsy of pregnancy, liver yang dizziness, liver fire headache. | |||
| TCMBANKHE004798 | 催吐萝芙木 | |||||
| TCMBANKHE007713 | Rauwolfia nitida | 光亮萝芙木 | ||||
| TCMBANKHE007001 | Cananga odorata | 依兰 | ||||
| TCMBANKHE006427 | Juniperus oxycedrus | 刺瑰 | ||||
| TCMBANKHE008552 | Herba Capsellae | 荠菜 | 1. Cool the blood and stop bleeding. 2. Clear away heat and promote diuresis. 3. Lower blood pressure./Blood ejection, spontaneous external bleeding, hemoptysis, hematuria, flooding and spotting, red eyes with gall, eyeground hemorrhage, hypertension, red and white dysentery, nephritis with edema, chyluria. | |||
| TCMBANKHE006424/YEM-192 | Rauvolfia yunnanensis|Rauvolfia yunnanensis Tsiang | 云南萝芙木 | 云南萝芙木 | 云南民族药物志：第一卷 | To clear heat and calm liver, resolve toxin and kill worms./Hypertension due to ascendant liver yang , headache, dizziness, vexation and agitation with insomnia, scab and lichen, snake bite. | 傣族/哈尼族/基诺族/景颇族/拉祜族/佤族/彝族 |
| TCMBANKHE004064/YEM-898 | Rauvolfia verticillata|Rauvolfia verticillata(Lour.)Baill. | 萝芙木 | 萝芙木 | 云南民族药物志：第五卷 | To clear heat, lower blood pressure, quiet spirit./Common cold with fever, headache and generalized pain, swelling pain in throat, hypertension, dizziness, insomnia, gan accumulation. | 傣族/瑶族/彝族/壮族 |
植物对应的疾病
| 疾病ID | 病名 | 疾病类型 | MeSH | 参考文献 |
|---|
| TCMBANKDI000002 | Hyperalgesia | phenotype | Pathological Conditions, Signs and Symptoms; Nervous System Diseases | 25572945 |
| TCMBANKDI000020 | Anxiety | disease | Behavior and Behavior Mechanisms | 28726252 |
| TCMBANKDI000056 | Heart failure | disease | Cardiovascular Diseases | 27659409 |
| TCMBANKDI000921 | Blood Pressure | phenotype | - | 22311903 |
| TCMBANKDI003236 | Impulsive Behavior | phenotype | Behavior and Behavior Mechanisms | 22334120 |
| TCMBANKDI006012 | Neuralgia | phenotype | Pathological Conditions, Signs and Symptoms; Nervous System Diseases | 25572945 |
| TCMBANKDI013952 | Memory, Episodic | phenotype | - | 27335220 |
| TCMBANKDI016058 | Psychological Trauma | disease | Mental Disorders | 27335220 |
| TCMBANKDI020247 | Cardiomegaly | phenotype | Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases | 27659409 |
| TCMBANKDI021368 | Shy-Drager Syndrome | disease | Nervous System Diseases; Cardiovascular Diseases | 22311903 |
| TCMBANKDI029264 | Anxiety Disorders | group | Mental Disorders | 24237691 |
| TCMBANKDI029850 | Sleep Apnea, Obstructive | disease | Respiratory Tract Diseases; Nervous System Diseases | 28239660 |
化合物对应的靶点
| 靶点ID | 基因名 | 基因别名 | 描述 |
|---|
| TCMBANKGE000121 | KCNH2 | ERG-1; ERG1; H-ERG; HERG; HERG1; Kv11.1; LQT2; SQT1 | potassium voltage-gated channel subfamily H member 2 |
| TCMBANKGE000181 | PIM1 | PIM | Pim-1 proto-oncogene, serine/threonine kinase |
| TCMBANKGE000201 | ESR1 | ER; ESR; ESRA; ESTRR; Era; NR3A1 | estrogen receptor 1 |
| TCMBANKGE000205 | NOS2 | HEP-NOS; INOS; NOS; NOS2A | nitric oxide synthase 2 |
| TCMBANKGE000286 | GSK3B | - | glycogen synthase kinase 3 beta |
| TCMBANKGE000309 | SCN5A | CDCD2; CMD1E; CMPD2; HB1; HB2; HBBD; HH1; ICCD; IVF; LQT3; Nav1.5; PFHB1; SSS1; VF1 | sodium voltage-gated channel alpha subunit 5 |
| TCMBANKGE000360 | CCNA2 | CCN1; CCNA | cyclin A2 |
| TCMBANKGE000425 | DRD1 | DADR; DRD1A | dopamine receptor D1 |
| TCMBANKGE000478 | CHEK1 | CHK1 | checkpoint kinase 1 |
| TCMBANKGE000598 | MDK | ARAP; MK; NEGF2 | midkine |
| TCMBANKGE000633 | ADRB2 | ADRB2R; ADRBR; B2AR; BAR; BETA2AR | adrenoceptor beta 2 |
| TCMBANKGE000701 | ESR2 | ER-BETA; ESR-BETA; ESRB; ESTRB; Erb; NR3A2; ODG8 | estrogen receptor 2 |
| TCMBANKGE000766 | ACHE | ACEE; ARACHE; N-ACHE; YT | acetylcholinesterase (Cartwright blood group) |
| TCMBANKGE000784 | CALM3 | CALM; CAM1; CAM2; CAMB; CPVT6; CaM; CaMIII; HEL-S-72; LQT16; PHKD; PHKD3 | calmodulin 3 |
| TCMBANKGE000813 | DPP4 | ADABP; ADCP2; CD26; DPPIV; TP103 | dipeptidyl peptidase 4 |
| TCMBANKGE000903 | PTGS1 | COX1; COX3; PCOX1; PES-1; PGG/HS; PGHS-1; PGHS1; PHS1; PTGHS | prostaglandin-endoperoxide synthase 1 |
| TCMBANKGE000938 | CDK2 | CDKN2; p33(CDK2) | cyclin dependent kinase 2 |
| TCMBANKGE001073 | PTGS2 | COX-2; COX2; GRIPGHS; PGG/HS; PGHS-2; PHS-2; hCox-2 | prostaglandin-endoperoxide synthase 2 |
| TCMBANKGE001185 | PPARG | CIMT1; GLM1; NR1C3; PPARG1; PPARG2; PPARG5; PPARgamma | peroxisome proliferator activated receptor gamma |
| TCMBANKGE001194 | ADRA2A | ADRA2; ADRA2R; ADRAR; ALPHA2AAR; ZNF32 | adrenoceptor alpha 2A |
| TCMBANKGE001202 | MAPK14 | CSBP; CSBP1; CSBP2; CSPB1; EXIP; Mxi2; PRKM14; PRKM15; RK; SAPK2A; p38; p38ALPHA | mitogen-activated protein kinase 14 |
| TCMBANKGE001506 | ADRA1B | ADRA1; ALPHA1BAR | adrenoceptor alpha 1B |
| TCMBANKGE001943 | ADRA1D | ADRA1; ADRA1A; ADRA1R; ALPHA1; DAR; dJ779E11.2 | adrenoceptor alpha 1D |
| TCMBANKGE003157 | CHRM2 | HM2 | cholinergic receptor muscarinic 2 |
| TCMBANKGE003625 | SLC6A4 | 5-HTT; 5-HTTLPR; 5HTT; HTT; OCD1; SERT; SERT1; hSERT | solute carrier family 6 member 4 |
| TCMBANKGE004266 | AR | AIS; AR8; DHTR; HUMARA; HYSP1; KD; NR3C4; SBMA; SMAX1; TFM | androgen receptor |
| TCMBANKGE005535 | CHRM1 | HM1; M1; M1R | cholinergic receptor muscarinic 1 |
| TCMBANKGE006943 | CHRM3 | EGBRS; HM3; PBS | cholinergic receptor muscarinic 3 |
| TCMBANKGE008056 | ADRA2C | ADRA2L2; ADRA2RL2; ADRARL2; ALPHA2CAR | adrenoceptor alpha 2C |
| TCMBANKGE008124 | ADRA2B | ADRA2L1; ADRA2RL1; ADRARL1; ALPHA2BAR; FAME2; alpha-2BAR | adrenoceptor alpha 2B |
| TCMBANKGE008702 | OPRM1 | LMOR; M-OR-1; MOP; MOR; MOR1; OPRM | opioid receptor mu 1 |
| TCMBANKGE008857 | LPL | HDLCQ11; LIPD | lipoprotein lipase |
| TCMBANKGE009455 | CHRM5 | HM5 | cholinergic receptor muscarinic 5 |
| TCMBANKGE011079 | PRSS1 | TRP1; TRY1; TRY4; TRYP1 | serine protease 1 |
| TCMBANKGE011342 | NGF | Beta-NGF; HSAN5; NGFB | nerve growth factor |
| TCMBANKGE011923 | CHRM4 | HM4; M4R | cholinergic receptor muscarinic 4 |
| TCMBANKGE012345 | DRD3 | D3DR; ETM1; FET1 | dopamine receptor D3 |
| TCMBANKGE013226 | DRD4 | D4DR | dopamine receptor D4 |
| TCMBANKGE014423 | ADRA1A | ADRA1C; ADRA1L1; ALPHA1AAR | adrenoceptor alpha 1A |
| TCMBANKGE014625 | OPRD1 | DOP; DOR; DOR1; OPRD | opioid receptor delta 1 |
| TCMBANKGE014790 | ADRB1 | ADRB1R; B1AR; BETA1AR; FNSS2; RHR | adrenoceptor beta 1 |
滇ICP备16009434号-1 |
Dai SX Lab